Expression of the matrix metaloproteinase 9 in Hodgkin's disease is independent of EBV status

Journal of Clinical Pathology - Molecular Pathology

Volumn 53, Issue 3, 2000, Pages 145-149

  Flavell, J R ^a   Baumforth, K R N ^a   Lowe, D ^a   Murray, P G ^a   Nelson, P N ^a   Williams, D M ^b   Lukesova, M ^c   Madarova, J ^c   Noskova, V ^c   Prochazkova, J ^c   Kolar, Z ^c  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Epstein Barr virus; Hodgkin's disease; Latent membrane protein 1; Matrix metalloproteinase 9

Indexed keywords

GELATINASE B; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN; TUMOR MARKER;

ARTICLE; CANCER SURVIVAL; CORRELATION FUNCTION; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; CELL CULTURE; ENZYME IMMUNOASSAY; ENZYMOLOGY; ISOLATION AND PURIFICATION; METABOLISM; SURVIVAL RATE; VIROLOGY; WESTERN BLOTTING;

BLOTTING, WESTERN; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IMMUNOENZYME TECHNIQUES; MATRIX METALLOPROTEINASE 9; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VIRAL MATRIX PROTEINS;

EID: 0034200452     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.53.3.145     Document Type: Article

References (29)

1. 1 Cossman J, Messineo C, Bagg A. Reed-Sternberg cell: survival in a hostile sea. Lab Invest 1998;78:229-35.
2. 2 Kuppers R, Rajewsky K. The origin of Hodgkin and Reed/ Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998;16:471-93.
3. 3 Yoshizaki T, Sato H, Furukawa M, et al. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci U S A 1998;95:3621-6.
4. 4 Trocme C, Gaudin P, Berthier S, et al. Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9. J Biol Chem 1998;273: 20677-84.
5. 5 Gokaslan ZL, Chintala SK, York JE, et al. Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors. Clin Exp Metastasis 1998;16: 721-8.
6. 6 Kossakowska AE, Hinek A, Edwards DR, et al. Proteolytic activity of human non-Hodgkin's lymphomas. Am J Pathol 1998;152:565-76.
7. 7 Kossakowska AE, Huchcroft SA, Urbanski SJ, et al. Comparative analysis of the expression patterns of metallo-proteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphoma in humans. Br J Cancer 1996;73:1401-8.
8. 8 Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994; 84:1361-92.
9. 9 Stein H, Gerdes J, Kirchner H, et al. Hodgkin and Sternberg-Reed cell antigen(s) detected by an antiserum to a cell line (L428) derived from Hodgkin's disease. Int J Cancer 1981;28:425-9.
10. 10 Burrichter H, Schaadt M, Diehl V. Conclusions from Hodgkin-derived cell lines. Cancer Treat Res 1989;41:29 41.
11. 11 Drexler HG, Leber BF, Norton J, et al. Genotypes and immunophenotypes of Hodgkin's disease-derived cell lines. Leukaemia 1988;2:371-6.
12. 12 Diehl V, Pfreundschuh M, Fonatsch C, et al. Phenotypic and genotypic analysis of Hodgkin's disease derived cell lines: histopathological and clinical implications. Cancer Surv 1985;4:399-419
13. 13 Kossakowska AE, Urbanski SJ, Edwards DR. Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas. Blood 1991;77:2475-81.
14. 14 Kossakowska AE, Urbanski SJ, Huchcroft SA, et al. Relationship between the clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (type IV collagenase) and tissue inhibitor of metalloproteinases-1 (TIMP-1) RNAs. Oncol Res 1992;4: 233-40.
15. 15 Kossakowska AE, Urbanski SJ, Watson A, et al. Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. Oncol Res 1993;5: 19-28.
16. 16 Wang F, Gregory C, Sample C, et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMPI cooperatively induce CD23. J Virol 1990;64:2309-18.
17. 17 Nakagomi H, Dolcetti R, Bejarano MT, et al. The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer 1994;57:240-4.
18. 18 Huen DS, Henderson SA, Croom-Carter D, et al. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10: 549-60.
19. 19 Gregory CD, Dive C, Henderson S, et al. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 1991;349:612-14.
20. 20 Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-15.
21. 21 Wang S, Rowe M, Lundgren E. Expression of the Epstein Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B-cell lines. Cancer Res 1996;56:4610-13.
22. 22 Laherty CD, Hu HM, Opipari AW, et al. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 1992;267:24157-60.
23. 23 Devergne O, Hatzivassiliou E, Izumi KM, et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-(kappa)B activation. Mol Cell Biol 1996;16:7098-108.
24. 24 Eliopoulos AG, Young LS. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 1998;16:1731-42.
25. 25 Pallesen G, Hamilton-Dutoit SJ, Rowe M, et al. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991;337:320-2.
26. 26 Murray PG, Young LS, Rowe M, et al. Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease. J Pathol 1992;166:1-5.
27. 27 Takeshita H, Yoshizaki T, Miller WE, et al. Matrix metallo-proteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol 1999;73:5548-55.
28. 28 Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996;87:4340-7.
29. 29 Krappmann D, Emmerich F, Kordes U, et al. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999;18:943-53.